
JLL Life Sciences Real Estate Outlook: Boom times continue for Boston metro area
Availability of space for new labs is a key selling point
In the annual beauty contest for best places to site new biopharma activity, the
JLL bases its assessment on a compilation of several factors: availability of life sciences professionals, and their proportion relative to other types of local or regional employment; destinations of venture capital funding and government research grants; and volume of available or potential laboratory space. This analysis is skewed toward selecting the location of new startups or new business units; the logic is that the R&D centers will be close to both corporate headquarters and, preferably, close to where in-house or contract manufacturing can occur.
JLL cites the explosion in investment in life sciences over the past couple years; the firm notes that $38 billion in investment funding has been raised by the industry in the first half of 2021, “an increase of 77% from the first half of 2020 and well over the 10-year average of 18% annual growth.” Industry financial health will also be boosted by the rising volume of pharma sales (at least, unless Washington drug-pricing restrictions take hold); sales will tick upward by a compound annual rate of 7.4% through 2026—faster than the 2.9% growth of the previous six years.
JLL’s report also presents a few details on the prospect of converting office space to lab/R&D space—something that pharma companies might be thinking of, given the still-uncertain situation of work-from-home employees returning to their offices. Such conversions require 16-ft minimum floor-to-floor heights (to make space for both “above ceiling mechanical systems” and “below-slab plumbing,” among other factors. “Investors and developers considering this option will need to invest $135 to $400 per square foot depending on the geography and scope of conversion required.”




